key: cord-0799916-y5059a0m
authors: Madan, Bharat; Reddem, Eswar R.; Wang, Pengfei; Casner, Ryan G.; Nair, Manoj S.; Huang, Yaoxing; Fahad, Ahmed S.; de Souza, Matheus Oliveira; Banach, Bailey B.; López Acevedo, Sheila N.; Pan, Xiaoli; Nimrania, Rajani; Teng, I‐Ting; Bahna, Fabiana; Zhou, Tongqing; Zhang, Baoshan; Yin, Michael T.; Ho, David D.; Kwong, Peter D.; Shapiro, Lawrence; DeKosky, Brandon J.
title: Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS‐CoV‐2
date: 2021-10-04
journal: AIChE J
DOI: 10.1002/aic.17440
sha: 65c810c58a785e3a29af7c5c2d944e3b8b714223
doc_id: 799916
cord_uid: y5059a0m

Antiviral monoclonal antibody (mAb) discovery enables the development of antibody‐based antiviral therapeutics. Traditional antiviral mAb discovery relies on affinity between antibody and a viral antigen to discover potent neutralizing antibodies, but these approaches are inefficient because many high affinity mAbs have no neutralizing activity. We sought to determine whether screening for anti‐SARS‐CoV‐2 mAbs at reduced pH could provide more efficient neutralizing antibody discovery. We mined the antibody response of a convalescent COVID‐19 patient at both physiological pH (7.4) and reduced pH (4.5), revealing that SARS‐CoV‐2 neutralizing antibodies were preferentially enriched in pH 4.5 yeast display sorts. Structural analysis revealed that a potent new antibody called LP5 targets the SARS‐CoV‐2 N‐terminal domain supersite via a unique binding recognition mode. Our data combine with evidence from prior studies to support antibody screening at pH 4.5 to accelerate antiviral neutralizing antibody discovery.

Monoclonal antibodies (mAbs) have been the fastest growing class of therapeutics over the past 30 years, with around 100 therapeutic mAbs approved for clinical use in the United States. 1 While binding to a viral surface antigen is a common feature to all these clinical mAbs, the most promising antiviral antibodies for clinical use show potent viral neutralization, or the ability to prevent viral infection in tissue culture. Increased neutralization potency, often quantified in vitro as a 50% inhibitory concentration (IC50) or an 80% inhibitory concentration (IC80), is often closely correlated with higher clinical efficacy. mAbs are often discovered from mining the unique B cells of humans or animal models exposed to viral protein antigens, either after infection or immunization. B cells contain both a variable heavy (VH) and variable light (VL) genes, and both must be sequenced together to characterize and discover the antibody as a potential mAb drug. Traditional hybridoma technologies and lower throughput methods like single B-cell cloning after limiting dilution and/or flow cytometric cell sorting (FACS) have led to numerous successful mAb products over the years 5, 6 ; these techniques rely on screening for binding antigen-binding activity of the antibodies encoded by B cells, followed by laborious mAb expression, purification, and neutralization assays with an anticipation that some fraction of the viral antigen-binding antibodies will neutralize. While binding is required for neutralization, it is often not directly correlated to neutralization potency. 7 Tremendous recent progress has been made in developing viral antigens that better replicate viral structures, thereby increasing the potential to identify neutralizing antibodies, but still only a fraction of the antibodies recovered have strong neutralization activity and associated therapeutic potential.

Antibody discovery technologies have proliferated from the earliest limiting dilution single cell studies using 96-well plates into faster and more efficient techniques. One approach employs droplet-based screening platforms and yeast display of the paired VH:VL repertoire from millions of B cells for functional antibody mining. 8, 9 Other approaches apply microfluidic chambers and microcapillary tubes for direct isolation and screening of antibody secreting cells without B-cell immortalization and library generation, 10 or droplet assays with antibody-secreting cells. 11 Increasingly common is the pairing of FACS-based antigen binding sorts of primary B cells with off-the-shelf transcriptome-based kits for larger scale sequencing of mAbs that bind to synthetic antigens. 12 Still, most extant antibody discovery technologies rely on binding affinity of antibodies to antigen(s) at serological pH conditions (pH 7.4), due to the viability requirements for sorted B cells, followed by a subsequent and laborious screening process of those binding hits in search of neutralization activity. Improved methods to more rapidly select for mAb clones with a higher probability of neutralizing activity will benefit the biochemical engineering community and reduce costs while enhancing the speed of potent antiviral mAb discovery.

In our prior work, we noticed that potent neutralizing antibodies targeting SARS-CoV-2 appeared to bind more tightly than nonneutralizing antibodies at non-serological pH (4.5-6.5). 13 Performing antibody screening at pH 4.5 may provide stringency to antibody selection from maintained binding outside of the protein-friendly pH 7.4 of serum.

Many viral families, including coronaviruses, can enter cells via endosomal pathways where structural changes to the viral fusion machinery can occur as the endosomal pH gradually reduces from serological pH 7.4 to pH 4.5-5.5 14, 15 ; therefore, endosomal pH (4.5-6.5) screening could help enrich for antibodies targeting certain conformations of viral fusion proteins. In particular, SARS-CoV-2 can enter cells via multiple pathways depending on the availability of proteases on the host cell surface, 16, 17 and endosomal entry pathways are also used by other flaviviruses including as dengue and yellow fever virus, and by filoviruses like Ebola virus. [18] [19] [20] [21] Based on the above information, we hypothesized that screening mAb libraries at pH 4.5 could preferentially identify the antiviral neutralizing antibodies targeting a potentially immunoevasive conformation of SARS-CoV-2 with an all-down orientation of the receptor binding domain (RBD) 15 in an antibody library. Here, we screened for SARS-CoV-2 neutralizing antibodies from a COVID-19 convalescent individual via yeast display screening at endosomal pH (4.5-5.5) , and also at pH 7.4. We isolated and characterized a panel of resulting antibodies, and found the novel and potently neutralizing antibody LP5 targeting the N-terminal domain (NTD) on the trimer spike glycoprotein.

These data, combined with knowledge collected in prior studies, 13 reveal that endosomal pH screening techniques can provide strong selective pressure that helps to enrich screening hits for neutralizing antibodies targeting SARS-CoV-2.

The peripheral blood mononuclear cell (PBMC) sample used in the study was collected at Columbia University Irving Medical Center in New York, New York. Patient recruitment and sample collection for this study occurred between March 25, 2020 and April 7, 2020. Informed consent was obtained prior to sample collection under IRB #AAAS9517.

2.2 | SARS-CoV-2 antigen probe generation for yeast display screening and ELISA experiments

The antigen probes used for yeast screening and ELISA experiments were produced as previously described. 22 Briefly, the DNA sequences encoding SARS-CoV-2 spike glycoprotein with two stabilizing proline mutations in S2 (S2P-Trimer) 23 and RBD were cloned in a mammalian expression vector and an AVI tag was placed after the coding sequence for biotinylation. The probes were produced by transient transfection of 293 Freestyle cells as previously described, 24 followed by affinity purification, tag-cleavage and biotinylation, and finally column purified. with AscI and NotI restriction enzymes into electrocompetent AWY101 9 yeast strain using a high efficiency yeast transformation method. 27 Transformed libraries were passaged twice in the synthetic defined media with casamino acids (SDCAA: 20 g/L dextrose, 6.7 g/L yeast nitrogen base, 5 g/L casamino acids, 8.56 g/L NaH 2 PO 4 .H 2 O, and 10.2 g/L Na 2 HPO 4 .7H 2 O) media to ensure single plasmid in each yeast cell, 27 and were subsequently analyzed by FACS for antibody discovery. Sorting was performed on a SONY MA900 cell sorter using associated software for sort data analysis. Sort gates were drawn for sorting as previously described. 9, 29 Fab expression and antigen binding were detected using the FITC and PE channels, respectively. Sorted yeast cells were grown in SDCAA (pH 4.5) to avoid bacterial contamination and expanded for 24-48 h at 30 C, 225 rpm. In subsequent rounds of sorting and affinity titrations, expanded samples in SDCAA were inoculated at an OD 600 0.2 in SGDCAA. In addition to collecting the antigen binding yeast cells, we collected yeast cells expressing Fab on yeast surface (referred as VL+) during the first round of screening by staining presort or input libraries with anti-FLAG-FITC conjugated mAb.

Yeast samples after each round of FACS were miniprepped using the protocol described previously. 9, 30, 31 Briefly, 4 Â 10 7 sorted yeast cells were expanded in SDCAA, centrifuged, and miniprepped to collect plasmid DNAs. Heavy and light chain antibody genes were amplified from miniprepped plasmid DNA samples using primers targeting the yeast display vector backbone. 9 Further rounds of PCR were used to add unique sample barcodes and Illumina adapters for analysis on a 2 Â 300 bp MiSeq platform. Raw Illumina sequencing data in FASTQ format were quality filtered and analyzed as described previously. 9,13,29,32 Clone enrichment across each round of sorting was tracked based on CDR-H3 amino acid sequences using enrichment ratios (ERs), which were calculated by determining the prevalence of a CDR-H3 amino acid sequence in each round of sorting divided by its prevalence in the Fab-expressing, or VL+, reference library. 29, 32 We used both Round 2 and Round 3 data for selecting antibody clones, as previously reported. 13, 29, 32 2.6 | Antibody protein expression and purification

The antibody coding heavy and light chain variable region genes were cloned into mammalian expression vectors for expression as IgG1. 9 The heavy and light chain genes were cotransfected into Expi293 mammalian cell line using an ExpiFectamine 293 Transfection Kit (Thermo Fischer Scientific) and cultured for 6 days in 37 C shaker at 125 RPM and 8% CO 2 .

At 6 days post transfection, cultures were centrifuged, supernatant collected, and IgGs purified using protein G resin (GenScript). If necessary, antibody proteins were concentrated using an Amicon Ultra-4 Centrifugal 30 kDa filtration unit (MilliporeSigma) and stored at 4 C. Super AquaBlue ELISA substrate (Thermo Fisher Scientific) was added to each well and incubated before reactions were stopped with 1 M oxalic acid. Absorbance was measured at 405 nm using a BioTek Synergy H1 plate reader. All ELISA experiments were performed in triplicate, except ELISAs against RBD were performed in duplicate.

Recombinant Indiana vesicular stomatitis virus (rVSV) was used for generating SARS-CoV-2 pseudovirus as previously described. 33 Human embryonic kidney (HEK) 293 T cells were grown to 80% confluency and transfected with SARS-CoV-2 WT, B.1.17, or B.1.351 spike gene using FuGENE 6 (Promega). 34 Cells were cultured overnight at 37 C with 5% CO 2 . VSV-G pseudotype ΔG-luciferase (G* ΔG-luciferase, Kerafast) was used to infect the cells in Dulbecco's modified Eagle medium (DMEM) at a multiplicity of infection (MOI) of 3 for 1 h. Cells were washed three times with 1Â Dulbecco's PBS without calcium and magnesium. DMEM supplemented with 2% fetal bovine serum, 100 IU/ml of penicillin and 100 μg/ml of streptomycin were added to the cells and cultured overnight. The supernatant was collected and clarified by centrifugation at 300 Â g for 10 min before storing at À80 C.

SARS-CoV-2 pseudovirus neutralization was performed as previously described. 33, 34 Briefly, neutralization was assessed by incubating rVSV expression SARS-CoV-2 pseudovirus with serial dilutions of purified antibody. Neutralization was determined by quantifying the reduction in luciferase gene activity.

Authentic virus neutralization for the purified antibodies was assessed as previously described. 33 Briefly, purified mAbs were serially diluted and incubated with infectious SARS-CoV-2 (BEI Resources) for 1 h at 37 C. The antibody-virus mixture was then transferred onto a monolayer of Vero-E6 cells and incubated for 72 h. Cytopathic effects caused by virus infection were visually observed and scored in a blind fashion by two independent observers.

Recombinant SARS-CoV-2 S2P spike was produced as previously described. 23 Data were collected on a Titan Krios electron microscope operating at 300 kV, equipped with a Gatan K3 direct electron detector and energy filter, using the SerialEM software package. 35 A total electron fluence of 41.92 eÀ/Å 2 was fractionated over 60 frames, with a total exposure time of 3.0 s. A magnification of 81,000Â resulted in a pixel size of 1.07 Å, and a defocus range of À0.8 to À2.5 μm was used. All processing was done using cryoSPARC 36 v3.2.0. Raw movies were aligned and dose-weighted using patch motion correction, and the contrast transfer function (CTF) was estimated using patch CTF estimation. Micrographs were picked using a blob picker, and a particle set was selected using 2D and 3D classification. Selected particle picks were manually curated for a small randomized subset of approximately 300 micrographs and used to train a Topaz neural network.

This network was then used to pick particles from the remaining micrographs, which were extracted with a box size of 448 pixels.

The final consensus 3D reconstruction was obtained using homogenous refinement with C3 symmetry. The interface between NTD and LP5 Fab was locally refined by using a mask that included NTD and the variable domains of the Fab. Half maps were provided to Resolve Cryo-EM tool in Phenix to support manual model building.

SARS CoV-2 S2P spike density was modeled using PDB entry 6XM5 as initial template. The initial model for LP5 Fab variable region was obtained using the SAbPred server. 37 Automated and manual model building were iteratively performed using real space refinement in Phenix 38 and Coot, 39 respectively. For 2-7, ISOLDE 40 v1.1 was also used to interactively refine the structure. Half maps were provided to Resolve Cryo-EM tool in Phenix to support manual model building. Geometry validation and structure quality assessment were performed using EMRinger 41 and MolProbity. 42 Map-fitting cross correlation (Fit-in-Map tool) and figures preparation were carried out using PyMOL and UCSF Chimera 43 and Chimera X. 44 A summary of cryo-EM data collection, reconstruction, and refinement statistics is shown in Table S1 .

PBMCs were collected from a patient who recovered from COVID-19 for subsequent antibody screening via yeast Fab display. First, we generated natively paired VH:VL gene amplicons using a single-cell F I G U R E 1 Functional analysis and screening of natively paired variable heavy:variable light (VH:VL) antibody repertoires from a convalescent COVID-19 patient. (A) Natively paired VH:VL antibody repertoires were generated from a COVID-19 convalescent donor for functional screening via yeast display. Left: Single B-cell capture using a flow-focusing device generating microdroplets consisting of a single B cell, lysis buffer, and oligo-dT magnetic beads. Single cells are emulsified and mRNA is captured onto magnetic beads used as template for overlap extension RT-PCR reactions to produce linked antibody VH and VL cDNAs; Center: Natively paired VH:VL cDNA amplicon libraries are cloned into a yeast display vector and expressed as Fabs for flow cytometric cell sorting (FACS) analysis at pH 7.4 and pH 4.5/5.5. Fab expression at pH 7.4 is detected by an anti-FLAG FITC-conjugated mAb; antigen binding is detected via PE-conjugated antigen probes. Fab expression is not measured at pH 4.5/5.5 due to markedly reduced binding affinity between FLAG expression tag. Screening of yeast-displayed natively paired VH:VL libraries against the SARS-CoV-2 spike glycoprotein with two stabilizing proline mutations in S2 domain (S2P-Trimer) and RBD antigens is shown via FACS at (B) pH 7.4 and (C) pH 4.5. IgK stands for antibodies encoding kappa light chains, and IgL for antibodies with lambda light chains. Substantial enrichment in antigen binding was observed after three rounds of sorting both at pH 7.4 and 4.5 compared to the presort/input libraries. See Figure S1 for sorting and enrichment at pH 5.5, and for an evaluation of expression and binding at pH 7.4 of yeast libraries sorted at pH 4.5/5.5 gene capture and overlap extension RT-PCR technology 9, 13 ( Figure 1A) . Briefly, antigen-experienced B cells were enriched by CD27+ selection and stimulated in vitro to enhance transcription of antibody genes. Single B cells were captured inside emulsion droplets for mRNA capture, and a subsequent overlap extension RT-PCR was used to transform the separate VH and VL genes into a single, physically linked VH:VL cDNA amplicon. VH:VL cDNAs were cloned into a yeast display vector to enable functional screening via FACS and NGS. 9, 13 Prior studies have shown that the majority of anti-SARS-CoV-2 neutralizing antibodies derive from mAbs encoded by the IgG heavy chain isotype, and we therefore focused on the IgG repertoire in this study. 45, 46 We generated two different libraries for yeast cloning and screening: IgG/V K for antibodies encoding kappa light chains, and IgG/V L for antibodies with lambda light chains. (Figures 1 and S1 ). Yeast antibody library sorting at pH 4.5/5.5 poses a challenge for the detection of Fab expression on yeast surface, as at pH 4.5 the binding affinity between the FLAG expression tag and its detecting antibody is markedly reduced. 50 To circumvent this issue, we sorted yeast without the use of the FLAG expression tag at pH 4.5/5.5, and then we confirmed that binding yeast were expressing the Fab/FLAG tag by staining with antigen at pH 4.5/5.5, and subsequently washing and changing the pH to 7.4 for labelling of the FLAG tag ( Figure S1 ). After three rounds of FACS and yeast culture in between sorts to enrich for antigen-binding Fabs in the yeast libraries, we observed that yeast sorted at endosomal pH showed strong expression and binding at pH 7.4 ( Figure S1B ,C).

We analyzed the plasmid DNAs encoded by yeast libraries across all sort conditions using 2 Â 300 bp Illumina MiSeq NGS analysis to quantitatively track the prevalence of each antibody clone in the libraries across screening rounds. 9, 13, 29, 32, 50 We followed each clone in the libraries by CDR-H3 amino acid sequences throughout the screening at all three pH values, calculating an ER for each clone (see Section 2). 9, 13, 29, 50 We used an ER cutoff of 10 to select clones for synthesis and characterization, and we chose five antibody sequences (LP1-LP5) that were enriched across various screening conditions for further analyses (Figure 2 ; Table 1 ).

We synthesized the VH and VL regions of LP1-5 mAbs and cloned them into human IgG1 expression plasmids for transient transfection in

Expi293F human cells and purification as full-length IgG for functional evaluation. ELISA studies demonstrated that all five mAbs bound to SARS-CoV-2 spike glycoprotein, with two mAbs (LP1 and LP2) targeting the RBD antigen. The remaining three mAbs (LP3-5) targeted the NTD of SARS-CoV-2 ( Figure 3) . Because LP2 and LP3 bind spike antigens in ELISA assays but do not neutralize pseudoviruses, it is likely that LP2 and LP3 target non-neutralizing epitopes on the spike protein.

We assessed the neutralization potency of each mAb against a SARS-CoV-2 pseudovirus based on VSV expressing the SARS-CoV-2 spike surface glycoprotein. 33 We first assayed the neutralization activity of the five mAbs against an early SARS-CoV-2 spike gene variant (Wuhan-Hu-1, China, or WT). Out of the five clones tested, LP5

showed the strongest neutralization activity with an IC50 <0.005 μg/ml ( Figure 4A ); LP1 also showed some neutralization activity ( Figure 4A ). Based on pseudovirus neutralization assay performance, we selected mAb LP5 for further neutralization studies.

We found that, out of the five antibody clones isolated from libraries here, LP5 showed the highest ratio of enrichment against the SARS-CoV-2 spike protein in our reduced pH library sorts (pH 4.5/5.5) compared to the library sorts at pH 7.4 ( Figure 2C,D) . mAb LP5 was also found to be the most potent antibody in neutralization assays ( Figure 4 ).

Our prior studies also revealed a similar association with binding to the spike at pH 4.5 with potent neutralizing activity against the conserved ACE2 binding site on the RBD domain. 13 Taken together, these data suggested that reduced pH sorts against the SARS-CoV-2 spike antigen may help to provide efficient selection of potent neutralizing antibodies.

To determine if LP5 would recognize recently emerged SARS-CoV-2 variants of concern (VOCs), 51 Figure 4B ). We also evaluated the neutralization activity of LP5 against SARS-CoV-2 WT and UK variant authentic viruses. LP5 neutralized an authentic SARS-CoV-2 WT virus with an IC50 0.038 μg/ml and showed over 60% neutralization of the UK variant, with an IC50 of 2.00 μg/ml against the UK strain ( Figure 4C ). Based on its neutralization performance features and strong recognition at endosomal pH, we selected LP5 for additional characterization and structural determination. pH has been supported both by the current study (targeting the RBD and the spike protein), and also in a prior study characterizing antibodies against the SARS-CoV-2 RBD. 13 These data suggest that endosomal pH screening could be a broadly useful tool to help preferentially identify potent antiviral antibodies and enhance screening efficiency while reducing the costs of antibody discovery campaigns.

We do not anticipate that every antibody that binds to viral antigens at endosomal pH will potently neutralize the virus; however, our data collected to date have revealed that most non-neutralizing antibodies do not bind to viral spike antigens to the same extent as the most potent neutralizing antibodies can recognize spike antigens at endosomal pH. 13 Screening for potent neutralizing antibodies at low pH will be a potential growth area for antibody discovery, and future studies will build on this initial report.

Based on the date and geographic location of sample collection in this study (New York, USA, March/April 2020), the COVID-19 convalescent donor was most likely infected with an early, founder-like virus strain. 33 Similar to data observed in other studies, 34 LP5 shows cross-reactive neutralization against the UK variant of concern (B.1.1.7), albeit with reduced potency. LP5 also shows some hallmarks of genetic and functional convergence with other reported anti-NTD recognition antibodies. LP5 is encoded by the VH3-33 heavy chain V-gene, which has also been observed in other potent anti-NTD supersite targeting mAb structures. 52-54 LP5, however, shows a slightly different mode of epitope recognition compared to its class members, as the unique glycan interactions from Lys57 HC and Arg66 HC have not been reported in other anti-NTD reported antibody structures to date.

In this study, we tested the capacity of endosomal pH screening to identify SARS-CoV-2 neutralizing antibodies, but we anticipate that endosomal pH screening can be useful to discover neutralizing antibodies against other viruses like YFV, dengue, rabies virus, and

Ebola virus, which all leverage endosomal entry pathways to infect cells. 19 replicating potential structural changes that viral fusion proteins undergo after endocytosis when the intraendosomal pH is reduced.

We note that yeast display is particularly suited for screening at pH 4.5-5.5, as yeast grows very well in the endosomal pH range.

Phage display screening at pH 4.5-5.5 should also work effectively.

Mammalian cell screening platforms are likely not compatible with endosomal pH screening due to the need to maintain high cell viability for most mammalian antibody screening platforms. We anticipate that endosomal pH screening as described here can help accelerate the identification of potent neutralizing antibodies against SARS-CoV-2 and other viral disease threats. While our current display platform has a limited ability to incorporate surface expression tags at pH 4.5, we will address this issue in future studies by the use of covalent tag-based detection of antibody gene expression that is not affected by endosomal pH. 50 We look forward to continued implementation of this simple and effective approach to rapidly downselect antibody libraries for potent antiviral neutralization activity and to enhance the efficiency of antibody discovery against emergent and established viral disease threats.

FDA approves 100th monoclonal antibody product

Phase 1 trial of a therapeutic anti-yellow fever virus human antibody

Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition

Monoclonal antibody therapy for Ebola virus disease

Broadly neutralizing antibodies to HIV and their role in vaccine design

Broadly neutralizing antiviral antibodies

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

In-depth determination and analysis of the human paired heavy-and light-chain antibody repertoire

Functional interrogation and mining of natively paired human VH:VL antibody repertoires

Rapid single B cell antibody discovery using nanopens and structured light

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies

Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses

pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN

Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Cell entry mechanisms of SARS-CoV-2

Flavivirus entry receptors: an update

Flavivirus cell entry and membrane fusion

Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis

Da Poian AT. Receptors and routes of dengue virus entry into the host cells

Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies

Ultrasonically-guided flow focusing generates precise emulsion droplets for high-throughput single cell analyses

Ultrahigh-throughput sequencing of the immune receptor repertoire from millions of lymphocytes

An improved yeast transformation method for the generation of very large human antibody libraries

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01

Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody

Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires

Characterizing protein-protein interactions using deep sequencing coupled to yeast surface display

Functional profiling of antibody immune repertoires in convalescent Zika virus disease patients. Front Immunol

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Automated electron microscope tomography using robust prediction of specimen movements

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

SAbPred: a structure-based antibody prediction server

Recent developments in the PHENIX software for automated crystallographic structure determination

Coot: model-building tools for molecular graphics

ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps

EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy

MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes

UCSF Chimera-a visualization system for exploratory research and analysis

UCSF ChimeraX: structure visualization for researchers, educators, and developers

COVID-19-neutralizing antibodies predict disease severity and survival

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

The covalent SNAP tag for protein display quantification and low-pH protein engineering

New SARS-CoV-2 variants-clinical, public health, and vaccine implications

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Double lock of a human neutralizing and protective monoclonal antibody targeting the yellow fever virus envelope

Flavivirus receptors: diversity, identity, and cell entry

Low-pH conformational changes of rabies virus glycoprotein and their role in membrane fusion

Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like conformation

Mechanisms of rabies virus neutralization

Antibody and virus: binding and neutralization

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

How to cite this article

Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2

https://orcid.org/0000-0002-7376-9991Manoj S. Nair https://orcid.org/0000-0002-5994-3957